| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Traws Pharma, Inc. (TRAW) has 11 insiders with recent SEC Form 4 filings, including 4 buys and 12 sells. TRAW is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 597.7K | $508.2K | - | |
| COO | 150.6K | $128.1K | - | |
| CEO | 147.8K | $125.6K | - | |
| Other | 116.0K | $98.6K | - | |
| Other | 113.9K | $96.9K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Nov 25, 2019 | Guerin Mark Patrick | Chief Financial Officer | Buy | 87,500 | $0.20 | $17,500.00 | +25,436% | |
| Nov 25, 2019 | Oler Abraham N. | VP Corp Dev &Gen Counsel | Buy | 75,000 | $0.20 | $15,000.00 | New | |
| Nov 25, 2019 | Fruchtman Steven M | President, Chief Executive Off | Buy | 149,000 | $0.20 | $29,800.00 | +34,977% | |
| Sep 25, 2019 | Marino James J | Director | Buy | 7,260 | $1.60 | $11,616.00 | +75.0% | |
| Sep 24, 2019 | Tyndall Capital Partners L P | 10% Owner | Sell | 16,700 | $1.19 | $19,873.00 | -2.6% | |
| Sep 23, 2019 | Armistice Capital, LLC56 | 10% Owner | Sell | 10,249 | $1.27 | $13,016.23 | -0.6% | |
| Sep 23, 2019 | Tyndall Capital Partners L P | 10% Owner | Sell | 112,361 | $1.49 | $167,397.66 | -7.9% | |
| Sep 18, 2019 | 683 Capital Management, LLC | Former 10% Owner | Sell | 506,877 | $2.03 | $1,030,684.29 | -14.0% | |
| Sep 18, 2019 | Tyndall Capital Partners L P | 10% Owner | Sell | 49,995 | $2.10 | $105,014.50 | -6.3% | |
| Sep 11, 2019 | Tyndall Capital Partners L P | 10% Owner | Sell | 1,247 | $2.75 | $3,432.49 | -0.2% |